Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Operating Leases (2024 - 2026)

Alto Neuroscience has reported Operating Leases over the past 3 years, most recently at $3.6 million for Q1 2026.

  • Quarterly results put Operating Leases at $3.6 million for Q1 2026, down 19.41% from a year ago — trailing twelve months through Mar 2026 was $3.6 million (down 19.41% YoY), and the annual figure for FY2025 was $3.8 million, down 29.02%.
  • Operating Leases reached $3.6 million in Q1 2026 per ANRO's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.4 million in Q4 2024 and bottomed at $3.6 million in Q1 2026.
  • Median Operating Leases over the past 3 years was $4.2 million (2025), compared with a mean of $4.4 million.
  • The largest annual shift saw Operating Leases decreased 29.02% in 2025 before it decreased 19.41% in 2026.
  • Over 3 years, Operating Leases stood at $5.4 million in 2024, then fell by 29.02% to $3.8 million in 2025, then fell by 7.01% to $3.6 million in 2026.
  • Business Quant data shows Operating Leases for ANRO at $3.6 million in Q1 2026, $3.8 million in Q4 2025, and $4.0 million in Q3 2025.